{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:44:39Z","timestamp":1793159079029,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40265-019-01252-4","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T06:02:41Z","timestamp":1578895361000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Zanubrutinib: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"11","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"8","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nri3487","volume":"13","author":"RC Rickert","year":"2013","unstructured":"Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13(8):578\u201391.","journal-title":"Nat Rev Immunol"},{"key":"1252_CR3","unstructured":"BeiGene. Brukinsa\u2122 (zanubrutinib) capsules, for oral use: US Prescribing Information; 2019. https:\/\/www.brukinsa.com. Accessed 10 Dec 2019."},{"key":"1252_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.HS9.0000560248.83366.72","volume":"3","author":"M Dimopoulos","year":"2019","unstructured":"Dimopoulos M, Opat S, Lee HP, et al. Major responses in Myd88 wildtype (Myd88wt) Waldenstrom macroglobulinemia (WM) patients treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) [abstract no. PF487]. HemaSphere. 2019;3:196.","journal-title":"HemaSphere."},{"key":"1252_CR5","unstructured":"BeiGene. BeiGene announces plan to pursue accelerated approval in the U.S. of BTK inhibitor zanubrutinib in Waldenstrm macroglobulinemia (WM) [media release]; 22 Jul 2018. http:\/\/www.beigene.com."},{"key":"1252_CR6","unstructured":"BieGene. BieGene Ltd. Form 10-K (28 February 2019); 2019. http:\/\/ir.beigene.com. Accessed 10 Dec 2019."},{"key":"1252_CR7","unstructured":"Catalent. Catalent to supply BeiGene\u2019s BTK inhibitor BRUKINSA\u2122 (zanubrutinib) [media release]. 21 Nov 2019. http:\/\/www.catalent.com."},{"issue":"2","key":"1252_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1535-7163.MCT-18-0478","volume":"18","author":"CJ Li","year":"2019","unstructured":"Li CJ, Jiang C, Liu Y, et al. Pleiotropic action of novel Bruton\u2019s tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma. Mol Cancer Ther. 2019;18(2):267\u201377.","journal-title":"Mol Cancer Ther"},{"key":"1252_CR9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220590","author":"TWH Flinsenberg","year":"2019","unstructured":"Flinsenberg TWH, Tromedjo CC, Hu N, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2019.220590.","journal-title":"Haematologica"},{"issue":"7","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.3324\/haematol.2018.214759","volume":"104","author":"C Tarantelli","year":"2019","unstructured":"Tarantelli C, Zhang L, Curti E, et al. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica. 2019;104(7):e307\u20139.","journal-title":"Haematologica"},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/0008-5472.CAN-15-3239","volume":"76","author":"N Hu","year":"2016","unstructured":"Hu N, Zhang S, He M, et al. BTK inhibitor BGB-3111 synergizes with lenalidomide in MCL models. Cancer Res. 2016;76:3.","journal-title":"Cancer Res"},{"issue":"4","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/hon.2667","volume":"37","author":"YX Zou","year":"2019","unstructured":"Zou YX, Zhu HY, Li XT, et al. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Hematol Oncol. 2019;37(4):392\u2013400.","journal-title":"Hematol Oncol"},{"key":"1252_CR13","unstructured":"Zhu J, Li J, Zhou J, et al. BGB-3111, a highly specific BTK inhibitor, is well tolerated and highly active in Chinese patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 trial in China [abstract]. Blood. 2017;130(Suppl 1)."},{"issue":"Suppl 2","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/hon.15_2629","volume":"37","author":"Y Song","year":"2019","unstructured":"Song Y, Zhou K, Zou D, et al. Zanubrutinib in patients with relapsed\/refractory mantle cell lymphoma [abstract no. 015]. Hematol Oncol. 2019;37(Suppl 2):45\u20136.","journal-title":"Hematol Oncol"},{"issue":"Suppl 2","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/hon.55_2630","volume":"37","author":"CS Tam","year":"2019","unstructured":"Tam CS, Wang M, Simpson D, et al. Updated safety and efficacy data in the phase 1 trial of patients with mantle cell lymphoma (MCL) treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) [abstract no. 191]. Hematol Oncol. 2019;37(Suppl 2):245\u20137.","journal-title":"Hematol Oncol"},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.HS9.0000560224.52872.d6","volume":"3","author":"J Trotman","year":"2019","unstructured":"Trotman J, Opat S, Marlton P, et al. Updated safety and efficacy data in a phase 1\/2 trial of patients with Waldenstrom macroglobulinaemia (WM) treated with the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) [abstract no. PF481]. HemaSphere. 2019;3:192\u20133.","journal-title":"HemaSphere"},{"issue":"Suppl 2","key":"1252_CR17","first-page":"537","volume":"2","author":"J Trotman","year":"2018","unstructured":"Trotman J, Tam CS, Marlton P, et al. Improved depth of response with increased follow-up for patients (PTS) with Waldenstrom macroglobulinemia (WM) treated with Bruton\u2019s tyrosine kinase (BTK) inhibitor zanubrutinib [abstract no. PS1186]. HemaSphere. 2018;2(Suppl 2):537\u20138.","journal-title":"HemaSphere"},{"issue":"Suppl 2","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/hon.2437_58","volume":"35","author":"J Trotman","year":"2017","unstructured":"Trotman J, Opat S, Marlton P, et al. Bruton\u2019s tyrosine kinase (BTK) inhibitor BGB-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenstrom macroglobulinemia (WM) [abstract no. 59]. Hematol Oncol. 2017;35(Suppl 2):70\u20131.","journal-title":"Hematol Oncol"},{"key":"1252_CR19","doi-asserted-by":"crossref","unstructured":"Tam CS, Robak P, Ghia P, et al. Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from arm C of the SEQUOIA (BGB-3111-304) trial [abstract no. 499]. In: American Society of Hematology annual meeting and exposition; 2019.","DOI":"10.1182\/blood-2019-125394"},{"issue":"Suppl 2","key":"1252_CR20","first-page":"87","volume":"37","author":"W Xu","year":"2019","unstructured":"Xu W, Yang S, Zhou K, et al. Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia [abstract no. 049]. Hematol Oncol. 2019;37(Suppl 2):87\u20138.","journal-title":"Hematol Oncol"},{"key":"1252_CR21","doi-asserted-by":"crossref","unstructured":"Cull G, Simpson D, Opat S, et al. Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): updated results from a phase 1\/2 trial [abstract no. 500]. In: American Society of Hematology annual meeting and exposition; 2019.","DOI":"10.1182\/blood-2019-125483"},{"key":"1252_CR22","unstructured":"Tam CS, Simpson D, Opat S, et al. Safety and activity of the highly specific BTK inhibitor BGB-3111 in patients with indolent and aggressive non-Hodgkin\u2019s lymphoma [abstract]. Blood. 2017;130(Suppl 1)."},{"key":"1252_CR23","unstructured":"Cull G, Opat S, Trotman J, et al. Safety and activity of the highly specific BTK inhibitor BGB-3111 in combination with the PD-1 inhibitor BGB-A317 in patients with B-cell lymphoid malignancies [abstract]. Blood. 2017;130(Suppl 1)."},{"issue":"Suppl 2","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.81_2629","volume":"37","author":"CS Tam","year":"2019","unstructured":"Tam CS, Quach H, Nicol A, et al. Zanubrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) or relapsed\/refractory (R\/R) follicular lymphoma (FL) [abstract no. 075]. Hematol Oncol. 2019;37(Suppl 2):121\u20132.","journal-title":"Hematol Oncol"},{"key":"1252_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/01.HS9.0000562920.26603.5b","volume":"3","author":"CS Tam","year":"2019","unstructured":"Tam CS, Opat S, Zhu J, et al. Pooled analysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies [abstract no. PS1159]. HemaSphere. 2019;3:526.","journal-title":"HemaSphere"},{"key":"1252_CR26","unstructured":"BeiGene. BeiGene announces results of phase 3 ASPEN trial of zanubrutinib compared to ibrutinib for the treatment of patients with Waldenstr\u00f6m\u2019s macroglobulinemia [media release]. 2019. http:\/\/ir.beigene.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01252-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T23:36:08Z","timestamp":1665444968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01252-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01252-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"13 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Syed is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}